This Project Grant award of $234,750.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will fund research at the University of Notre Dame to elucidate the interactions between three major uropathogens - E. coli, E. faecalis, and C. albicans - during catheter-associated urinary tract infections (CAUTI). The proposed studies aim to: 1) investigate E. coli's antagonistic effects on...
This $1.23 million Project Grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at Loyola University of Chicago from June 2022 to May 2025 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to further the university's investigation into how certain species of Lactobacillus bacteria found in the female urinary tract can control colonization of uropathogenic Escherichia coli (UPEC) through...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA program 93.855 "Allergy and Infectious Diseases Research," is providing $813,373 to Rutgers, The State University of New Jersey to conduct research on developing new classes of pyrazinoic acid prodrugs against pyrazinamide-resistant Mycobacterium tuberculosis. The goal is to characterize the diverse set of Mycobacterium tuberculosis amidases and the compound structures...
This federal Project Grant award, valued at $312,000.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will support research conducted by the University of Texas Health Science Center at Houston (UTHealth) to develop a single-cell resolution understanding of pathogenesis and antibiotic tolerance in Staphylococcus aureus infections. The research aims to explore the...
This $948,482 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research into the molecular mechanisms of the YbtPQ bacterial importer, a novel type of ATP-binding cassette (ABC) transporter found in uropathogenic E. coli. The primary goals are to define the substrate selectivity and inhibitory mechanisms of YbtPQ, as well as understand its unique structural motifs. Researchers at the University of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,388,838 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Research Foundation For The State University Of New York (RF SUNY) to optimize phage cocktail regimens for treating extensively drug-resistant Pseudomonas aeruginosa. The project aims to: 1) develop a quantification assay for the phage cocktail, 2) identify optimal phage combinations and administration patterns...
This federal Project Grant award for $153,540 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports research at Columbia University to perform human genome-wide association studies (GWAS) to identify genetic risk variants associated with urinary tract infections (UTIs). The research aims to discover novel genes and cell types involved in immune...
This Project Grant award of $828,820 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) supports research to elucidate the molecular mechanisms by which the commensal bacterium Enterococcus faecalis can translocate across the intestinal epithelial barrier and cause systemic infections. The research aims to define how E. faecalis disrupts endoplasmic reticulum proteostasis and activates the unfolded...
This $151,040 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the regulatory role of the small regulatory RNA BECO on essential virulence factors in the pathogen Pseudomonas aeruginosa. The research aims to determine how BECO controls the expression of the Type III Secretion System and pyochelin biosynthesis genes, which are critical for P....
This $664,744 federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research), will fund a randomized Phase I/II pilot clinical trial to evaluate the safety, tolerability, feasibility, and efficacy of phage therapy for reducing recurrent urinary tract infections (rUTIs) in female kidney transplant recipients. The trial will compare phage therapy targeting E. coli and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,608 to The Research Foundation For The State University Of New York (RF SUNY) to investigate the role of Proteus mirabilis RTX proteins in polymicrobial biofilm formation and pathogenesis of catheter-associated urinary tract infections (CAUTI). The research aims to examine how P. mirabilis RTX proteins mediate interactions between P. mirabilis and Enterococcus faecalis within polymicrobial biofilms, and determine the contribution of these proteins to CAUTI progression and severity. The project will utilize in vitro biofilm assays and a mouse model of CAUTI to elucidate the mechanisms by which P. mirabilis RTX proteins promote polymicrobial biofilm formation and enhance CAUTI pathogenesis. The findings have the potential to inform the development of novel therapeutics to disrupt these disease-promoting interactions and improve clinical interventions for CAUTI.